Issue: 2017 > June > case report

Transient thyrotoxicosis during nivolumab treatment

M.J. van Kooten1, G. van den Berg, A.W.J.M. Glaudemans, T.J.N. Hiltermann, H.J.M. Groen, A. Rutgers, T.P. Links
AbstractFull textPDF


Two patients presented with transient thyrotoxicosis within 2-4 weeks after starting treatment with nivolumab. This thyrotoxicosis turned into hypothyroidism within 6-8 weeks. Temporary treatment with a beta blocker may be sufficient.